Acta Med. 2021, 64: 187-192

https://doi.org/10.14712/18059694.2021.32

Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta

Štěpán Kutíleka,b,c, Ivana Plášilováa,c, Sylva Skálováa, Milan Bayera,d, Erika Ondrušováa

aDepartment of Pediatrics, Faculty of Medicine and Faculty Hospital in Hradec Králové, Charles University, Hradec Králové, Czech Republic
bDepartment of Pediatrics, Klatovy Hospital, Klatovy, Czech Republic
cDepartment of Pediatrics, Pardubice Hospital, Pardubice, Czech Republic
dDepartment of Pediatrics, 3rd Faculty of Medicine and University Hospital Královské Vinohrady, Charles University in Prague, Czech Republic

Received December 13, 2019
Accepted August 12, 2021

References

1. Sam JE, Dharmalingam M. Osteogenesis imperfecta. Indian J Endocr Metab 2017; 21: 903–8.
2. Dwan K, Phillipi CA, Steiner RD, Basel D.Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2016 Oct 19; 10:CD005088
3. Constantino CS, Krzak JJ, Fial AV, et al. Effect of bisphosphonates on function and mobility among children with osteogenesis imperfecta: A systematic review. J Bone Miner Res PLUS 2019; 3/10: e10216.
4. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 65: 654–61. <https://doi.org/10.1136/ard.2005.044958> <PubMed>
5. Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G. Efficacy and safety of monthly ibandronate in men with low bone density. Bone 2010; 46(4): 970–6. <https://doi.org/10.1016/j.bone.2009.12.034>
6. Cundy T, Wheadon L, King A. Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res 2004; 19: 703–11. <https://doi.org/10.1359/jbmr.040127>
7. Li M, Xia WB, Xing XP, et al. Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta. Chin Med J 2011; 124: 3049–53.
8. Ipach I, Kluba T, Wolf P, Pontz B, Mittag F. The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta. Orthop Rev (Pavia) 2012; 4: e29. <https://doi.org/10.4081/or.2012.e29> <PubMed>
9. Grenda R, Karczmarewicz E, Rubik J, et al. Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients—a prospective study. Pediatr Transplant 2011; 15: 205–13. <https://doi.org/10.1111/j.1399-3046.2010.01440.x>
10. Kutilek S, Plasilova I, Nemec V. Once-monthly oral ibandronate treatment in an adolescent with recurrent fractures and inadequately low bone mass. J Paediatr Child Health 2012; 48: 622–3. <https://doi.org/10.1111/j.1440-1754.2012.02498.x>
11. Kutilek S, Plasilova I, Langer J. Ibandronate in the treatment of pediatric osteoporosis. Indian Pediatr 2016; 53: 927.
12. Karahasanovic A, Thorsteinsson AL, Bjarnason NH, Eiken P. Long-term leukopenia in a lung transplanted patient with cystic fibrosis treated with zoledronic acid: a case report. Osteoporos Int 2016; 27: 2621–5. <https://doi.org/10.1007/s00198-016-3559-x>
13. van der Klauw MM, Goudsmit R, Halie MR, van’t Veer MB, Herings RM, Wilson JH, Stricker BH. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 1999; 159: 369–74. <https://doi.org/10.1001/archinte.159.4.369>
14. Hunt KA, Resnick MP. Clomipramine-induced agranulocytosis and its treatment with G-CSF. Am J Psychiatry 1993; 150: 522–3.
15. Burke MS, Josephson A, Lightsey A. Combined methylphenidate and imipramine complication. J Am Acad Child Adolesc Psychiatry 1995; 34: 403–4. <https://doi.org/10.1097/00004583-199504000-00006>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive